drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01246 | DB01268 | 820 | 1,151 | [
"DDInter45",
"DDInter1731"
] | Alimemazine | Sunitinib | A phenothiazine derivative that is used as an antipruritic. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
820,
24,
1151
]
],
[
[
820,
64,
1311
],
[
1311,
1,
1151
]
],
[
[
820,
6,
8374
],
[
8374,
45,
1151
]
],
[
[
820,
7,
9650
],
[
9650,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoc... | Alimemazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide (Compound) resembles Sunitinib (Compound)
Alimemazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sunitinib (Compound)
Alimemazine (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upr... |
DB00445 | DB01039 | 322 | 535 | [
"DDInter655",
"DDInter718"
] | Epirubicin | Fenofibrate | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993. | Moderate | 1 | [
[
[
322,
24,
535
]
],
[
[
322,
7,
5440
],
[
5440,
46,
535
]
],
[
[
322,
21,
28936
],
[
28936,
60,
535
]
],
[
[
322,
24,
522
],
[
522,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibrate"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"SOX2"
],
[
"SOX2",
"{u} (Gene) is upregulated by {v} (Co... | Epirubicin (Compound) upregulates SOX2 (Gene) and SOX2 (Gene) is upregulated by Fenofibrate (Compound)
Epirubicin (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Fenofibrate (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Z... |
DB09052 | DB11817 | 250 | 1,259 | [
"DDInter220",
"DDInter165"
] | Blinatumomab | Baricitinib | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
250,
25,
1259
]
],
[
[
250,
24,
949
],
[
949,
24,
1259
]
],
[
[
250,
63,
563
],
[
563,
24,
1259
]
],
[
[
250,
24,
1129
],
[
1129,
... | [
[
[
"Blinatumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (fo... | Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Blinatumo... |
DB04861 | DB06663 | 1,592 | 1,154 | [
"DDInter1271",
"DDInter1398"
] | Nebivolol | Pasireotide | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
1592,
24,
1154
]
],
[
[
1592,
63,
966
],
[
966,
40,
1154
]
],
[
[
1592,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
1592,
63,
959
],
[
959... | [
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Nebivolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
... | Nebivolol may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Nebivolol (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Nebivolol may cause a moderate int... |
DB00999 | DB09020 | 504 | 28 | [
"DDInter883",
"DDInter212"
] | Hydrochlorothiazide | Bisacodyl | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
504,
24,
28
]
],
[
[
504,
7,
4765
],
[
4765,
46,
28
]
],
[
[
504,
18,
12821
],
[
12821,
46,
28
]
],
[
[
504,
18,
9385
],
[
9385,
... | [
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Hydrochlorothiazide",
"{u} (Compound) upregulates {v} (Gene)",
"SGCB"
],
[
"SGCB",
"{u} (Gene) is upregu... | Hydrochlorothiazide (Compound) upregulates SGCB (Gene) and SGCB (Gene) is upregulated by Bisacodyl (Compound)
Hydrochlorothiazide (Compound) downregulates TRIB1 (Gene) and TRIB1 (Gene) is upregulated by Bisacodyl (Compound)
Hydrochlorothiazide (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is downregulated by... |
DB00734 | DB00804 | 1,664 | 1,507 | [
"DDInter1605",
"DDInter543"
] | Risperidone | Dicyclomine | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Moderate | 1 | [
[
[
1664,
24,
1507
]
],
[
[
1664,
21,
29231
],
[
29231,
60,
1507
]
],
[
[
1664,
24,
1021
],
[
1021,
63,
1507
]
],
[
[
1664,
63,
1594
],
[
... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Risperidone",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Sid... | Risperidone (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Dicyclomine (Compound)
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when... |
DB01166 | DB05812 | 477 | 1,374 | [
"DDInter379",
"DDInter8"
] | Cilostazol | Abiraterone | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
477,
24,
1374
]
],
[
[
477,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
477,
21,
28661
],
[
28661,
60,
1374
]
],
[
[
477,
25,
74
],
[
74,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Cilostazol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)"... | Cilostazol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Cilostazol (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Abiraterone (Compound)
Cilostazol may lead to a major life threatening interaction when taken with Boce... |
DB00405 | DB06691 | 128 | 849 | [
"DDInter517",
"DDInter1155"
] | Dexbrompheniramine | Mepyramine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
128,
24,
849
]
],
[
[
128,
1,
11775
],
[
11775,
40,
849
]
],
[
[
128,
40,
11244
],
[
11244,
1,
849
]
],
[
[
128,
74,
1594
],
[
1594,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Dexbrompheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Chloropyramine"
],
[
"Chloropyramine",
... | Dexbrompheniramine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound)
Dexbrompheniramine (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Mepyramine (Compound)
Dexbrompheniramine (Compound) resembles Doxylamine (Compound) and Dexb... |
DB00770 | DB09038 | 642 | 1,450 | [
"DDInter55",
"DDInter636"
] | Alprostadil | Empagliflozin | Alprostadil is a chemically-identical synthetic form of prostaglandin E1 (PGE1), a potent vasodilator produced endogenously. In 1996, the FDA approved the use of alprostadil, administered either with an intracavernosal injection or an intraurethral suppository, for the treatment of erectile dysfunction, and it is used ... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
642,
24,
1450
]
],
[
[
642,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
642,
24,
885
],
[
885,
24,
1450
]
],
[
[
642,
24,
1455
],
[
1455,
... | [
[
[
"Alprostadil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Alprostadil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Alprostadil may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Alprostadil may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol... |
DB01088 | DB01193 | 714 | 819 | [
"DDInter908",
"DDInter12"
] | Iloprost | Acebutolol | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Moderate | 1 | [
[
[
714,
24,
819
]
],
[
[
714,
63,
887
],
[
887,
1,
819
]
],
[
[
714,
24,
578
],
[
578,
62,
819
]
],
[
[
714,
63,
1479
],
[
1479,
23... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
],
[
"P... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinic... |
DB00321 | DB01142 | 21 | 1,264 | [
"DDInter78",
"DDInter593"
] | Amitriptyline | Doxepin | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
21,
35,
1264
]
],
[
[
21,
1,
508
],
[
508,
24,
1264
]
],
[
[
21,
40,
225
],
[
225,
1,
1264
]
],
[
[
21,
35,
401
],
[
401,
24,
... | [
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
... | Amitriptyline (Compound) resembles Doxepin (Compound) and
Amitriptyline (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Amitriptyline (Compound) resembles Thiothixene (Compound) and Thiothixene (Compound) resembles Doxepin (... |
DB00514 | DB00980 | 506 | 969 | [
"DDInter527",
"DDInter1564"
] | Dextromethorphan | Ramelteon | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Moderate | 1 | [
[
[
506,
24,
969
]
],
[
[
506,
6,
8374
],
[
8374,
45,
969
]
],
[
[
506,
21,
28714
],
[
28714,
60,
969
]
],
[
[
506,
63,
1324
],
[
1324,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (... | Dextromethorphan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ramelteon (Compound)
Dextromethorphan (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Ramelteon (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Trogl... |
DB00047 | DB09418 | 176 | 554 | [
"DDInter932",
"DDInter1501"
] | Insulin glargine | Potassium perchlorate | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Potassium perchlorate is an inorganic salt with the chemical formula KClO4. It is a strong oxidizer with the lowest solubility of the alkali metal perchlorates. Potassium is most commonly used in flares and automobile airbags . The use of potassium perchlorate as a component in sealing gaskets for food containers has b... | Minor | 0 | [
[
[
176,
23,
554
]
],
[
[
176,
24,
914
],
[
914,
24,
554
]
],
[
[
176,
23,
333
],
[
333,
23,
1254
],
[
1254,
23,
554
]
],
[
[
176,
2... | [
[
[
"Insulin glargine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Potassium perchlorate"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflun... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Potassium perchlorate
Insulin glargine may cause a minor interaction that can limit clinical effects when taken with ... |
DB01041 | DB08864 | 770 | 786 | [
"DDInter1789",
"DDInter1595"
] | Thalidomide | Rilpivirine | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
770,
24,
786
]
],
[
[
770,
24,
655
],
[
655,
1,
786
]
],
[
[
770,
6,
10215
],
[
10215,
45,
786
]
],
[
[
770,
21,
29343
],
[
29343,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Thalidomide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Rilpivirine (Compound)
Thalidomide (Compound) causes Blood creatinine increased (Si... |
DB04953 | DB14568 | 495 | 982 | [
"DDInter708",
"DDInter1000"
] | Ezogabine | Ivosidenib | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
495,
25,
982
]
],
[
[
495,
62,
112
],
[
112,
23,
982
]
],
[
[
495,
63,
543
],
[
543,
24,
982
]
],
[
[
495,
24,
28
],
[
28,
24,
... | [
[
[
"Ezogabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Ezogabine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazo... | Ezogabine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Lopera... |
DB01105 | DB01294 | 222 | 266 | [
"DDInter1665",
"DDInter215"
] | Sibutramine | Bismuth subsalicylate | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth s... | Moderate | 1 | [
[
[
222,
24,
266
]
],
[
[
222,
21,
28643
],
[
28643,
60,
266
]
],
[
[
222,
63,
1347
],
[
1347,
24,
266
]
],
[
[
222,
24,
235
],
[
235,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
]
],
[
[
"Sibutramine",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Ef... | Sibutramine (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Bismuth subsalicylate (Compound)
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when tak... |
DB00777 | DB08907 | 146 | 1,344 | [
"DDInter1537",
"DDInter280"
] | Propiomazine | Canagliflozin | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
146,
24,
1344
]
],
[
[
146,
24,
549
],
[
549,
1,
1344
]
],
[
[
146,
63,
176
],
[
176,
24,
1344
]
],
[
[
146,
24,
473
],
[
473,
2... | [
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]... | Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a modera... |
DB00209 | DB00831 | 352 | 1,178 | [
"DDInter1886",
"DDInter1866"
] | Trospium | Trifluoperazine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Moderate | 1 | [
[
[
352,
24,
1178
]
],
[
[
352,
24,
695
],
[
695,
40,
1178
]
],
[
[
352,
24,
9
],
[
9,
1,
1178
]
],
[
[
352,
6,
4304
],
[
4304,
45,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Trifluoperazine (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Methotrimeprazine and Methotrimeprazine (Compound) resembles Trifluope... |
DB01156 | DB11915 | 593 | 1,293 | [
"DDInter252",
"DDInter1909"
] | Bupropion | Valbenazine | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Major | 2 | [
[
[
593,
25,
1293
]
],
[
[
593,
24,
516
],
[
516,
24,
1293
]
],
[
[
593,
64,
401
],
[
401,
24,
1293
]
],
[
[
593,
25,
820
],
[
820,
... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valbenazine"
]
],
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[
"Levocet... | Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Bupropion may lead to a major life threatening interaction when taken with Promethazine and Promethazine... |
DB06335 | DB08875 | 761 | 1,618 | [
"DDInter1646",
"DDInter262"
] | Saxagliptin | Cabozantinib | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
761,
24,
1618
]
],
[
[
761,
63,
723
],
[
723,
24,
1618
]
],
[
[
761,
24,
384
],
[
384,
63,
1618
]
],
[
[
761,
62,
307
],
[
307,
... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Id... |
DB00398 | DB14723 | 79 | 159 | [
"DDInter1702",
"DDInter1026"
] | Sorafenib | Larotrectinib | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
79,
24,
159
]
],
[
[
79,
24,
479
],
[
479,
23,
159
]
],
[
[
79,
25,
318
],
[
318,
23,
159
]
],
[
[
79,
64,
1230
],
[
1230,
23,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Sorafenib may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause... |
DB00307 | DB06605 | 1,101 | 1,409 | [
"DDInter202",
"DDInter108"
] | Bexarotene | Apixaban | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
1101,
24,
1409
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
1409
]
],
[
[
1101,
21,
29666
],
[
29666,
60,
1409
]
],
[
[
1101,
24,
307
],
[
30... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Apixaban (Compound)
Bexarotene (Compound) causes Melaena (Side Effect) and Melaena (Side Effect) is caused by Apixaban (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may... |
DB00344 | DB12500 | 1,302 | 283 | [
"DDInter1543",
"DDInter714"
] | Protriptyline | Fedratinib | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1302,
24,
283
]
],
[
[
1302,
25,
351
],
[
351,
23,
283
]
],
[
[
1302,
24,
1419
],
[
1419,
24,
283
]
],
[
[
1302,
63,
600
],
[
600,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribo... | Protriptyline may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause ... |
DB01276 | DB11921 | 123 | 1,019 | [
"DDInter706",
"DDInter492"
] | Exenatide | Deflazacort | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
123,
24,
1019
]
],
[
[
123,
63,
1072
],
[
1072,
23,
1019
]
],
[
[
123,
24,
192
],
[
192,
24,
1019
]
],
[
[
123,
63,
443
],
[
443,
... | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
... | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens and E... |
DB00401 | DB09112 | 84 | 1,455 | [
"DDInter1298",
"DDInter1306"
] | Nisoldipine | Nitrous acid | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
84,
24,
1455
]
],
[
[
84,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
84,
1,
336
],
[
336,
24,
1455
]
],
[
[
84,
40,
854
],
[
854,
24,... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
... | Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Nisoldipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction ... |
DB00995 | DB01073 | 1,112 | 1,488 | [
"DDInter139",
"DDInter745"
] | Auranofin | Fludarabine | Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme ox... | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Moderate | 1 | [
[
[
1112,
24,
1488
]
],
[
[
1112,
21,
28725
],
[
28725,
60,
1488
]
],
[
[
1112,
24,
36
],
[
36,
63,
1488
]
],
[
[
1112,
63,
522
],
[
522,
... | [
[
[
"Auranofin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Auranofin",
"{u} (Compound) causes {v} (Side Effect)",
"Pancytopenia"
],
[
"Pancytopenia",
"{u} (Side Effect) is... | Auranofin (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Fludarabine (Compound)
Auranofin may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Fludar... |
DB08826 | DB09570 | 1,292 | 1,480 | [
"DDInter489",
"DDInter1002"
] | Deferiprone | Ixazomib | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Major | 2 | [
[
[
1292,
25,
1480
]
],
[
[
1292,
64,
268
],
[
268,
24,
1480
]
],
[
[
1292,
25,
1598
],
[
1598,
63,
1480
]
],
[
[
1292,
24,
1017
],
[
1017... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon alfa-2b"
],
[
"Peginterferon ... | Deferiprone may lead to a major life threatening interaction when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Deferiprone may lead to a major life threatening interaction when taken with Tazemetostat and Tazemetostat... |
DB00624 | DB09054 | 1,561 | 384 | [
"DDInter1776",
"DDInter905"
] | Testosterone (topical) | Idelalisib | Testosterone is an androstanoid having 17beta-hydroxy and 3-oxo groups, together with unsaturation at C-4-C-5.. It has a role as an androgen, a human metabolite, a Daphnia magna metabolite and a mouse metabolite. It is a 17beta-hydroxy steroid, an androstanoid, a C19-steroid and a 3-oxo-Delta(4) steroid. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1561,
24,
384
]
],
[
[
1561,
63,
305
],
[
305,
24,
384
]
],
[
[
1561,
24,
891
],
[
891,
24,
384
]
],
[
[
1561,
40,
1687
],
[
1687,
... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichi... | Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate dise... |
DB00843 | DB01010 | 479 | 61 | [
"DDInter583",
"DDInter622"
] | Donepezil | Edrophonium | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. | Moderate | 1 | [
[
[
479,
24,
61
]
],
[
[
479,
6,
5765
],
[
5765,
45,
61
]
],
[
[
479,
21,
29103
],
[
29103,
60,
61
]
],
[
[
479,
24,
1011
],
[
1011,
... | [
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
]
],
[
[
"Donepezil",
"{u} (Compound) binds {v} (Gene)",
"ACHE"
],
[
"ACHE",
"{u} (Gene) is bound by {v} (Compound)",
... | Donepezil (Compound) binds ACHE (Gene) and ACHE (Gene) is bound by Edrophonium (Compound)
Donepezil (Compound) causes Muscle contractions involuntary (Side Effect) and Muscle contractions involuntary (Side Effect) is caused by Edrophonium (Compound)
Donepezil may cause a moderate interaction that could exacerbate disea... |
DB00356 | DB01176 | 1,315 | 537 | [
"DDInter366",
"DDInter453"
] | Chlorzoxazone | Cyclizine | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
1315,
24,
537
]
],
[
[
1315,
63,
1242
],
[
1242,
24,
537
]
],
[
[
1315,
24,
13
],
[
13,
24,
537
]
],
[
[
1315,
21,
28778
],
[
28778,
... | [
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
... | Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine a... |
DB00283 | DB00405 | 701 | 128 | [
"DDInter395",
"DDInter517"
] | Clemastine | Dexbrompheniramine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Moderate | 1 | [
[
[
701,
24,
128
]
],
[
[
701,
24,
662
],
[
662,
63,
128
]
],
[
[
701,
6,
10104
],
[
10104,
45,
128
]
],
[
[
701,
23,
771
],
[
771,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Clemastine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Dexbrompheniramine (Compound)
... |
DB00191 | DB00331 | 73 | 1,645 | [
"DDInter1447",
"DDInter1164"
] | Phentermine | Metformin | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Moderate | 1 | [
[
[
73,
24,
1645
]
],
[
[
73,
21,
28714
],
[
28714,
60,
1645
]
],
[
[
73,
24,
1647
],
[
1647,
23,
1645
]
],
[
[
73,
24,
1178
],
[
1178,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
]
],
[
[
"Phentermine",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is cause... | Phentermine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Metformin (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Metformin
Phen... |
DB00831 | DB01041 | 1,178 | 770 | [
"DDInter1866",
"DDInter1789"
] | Trifluoperazine | Thalidomide | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1178,
24,
770
]
],
[
[
1178,
6,
7950
],
[
7950,
45,
770
]
],
[
[
1178,
7,
7669
],
[
7669,
46,
770
]
],
[
[
1178,
21,
28892
],
[
28892,... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (... | Trifluoperazine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Thalidomide (Compound)
Trifluoperazine (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Thalidomide (Compound)
Trifluoperazine (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by T... |
DB00414 | DB00543 | 590 | 87 | [
"DDInter16",
"DDInter82"
] | Acetohexamide | Amoxapine | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Moderate | 1 | [
[
[
590,
24,
87
]
],
[
[
590,
24,
623
],
[
623,
40,
87
]
],
[
[
590,
63,
695
],
[
695,
40,
87
]
],
[
[
590,
63,
867
],
[
867,
1,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Amoxapine (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Amoxapine (Compound... |
DB00731 | DB12130 | 1,144 | 1,017 | [
"DDInter1269",
"DDInter1094"
] | Nateglinide | Lorlatinib | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1144,
24,
1017
]
],
[
[
1144,
63,
590
],
[
590,
24,
1017
]
],
[
[
1144,
24,
1491
],
[
1491,
24,
1017
]
],
[
[
1144,
24,
1654
],
[
1654... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin a... |
DB00959 | DB09035 | 1,486 | 410 | [
"DDInter1191",
"DDInter1308"
] | Methylprednisolone | Nivolumab | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation _S228P_ for additional stability and reduced variability. It was developed by Bristol Myers Squibb. N... | Moderate | 1 | [
[
[
1486,
24,
410
]
],
[
[
1486,
40,
1573
],
[
1573,
24,
410
]
],
[
[
1486,
1,
175
],
[
175,
24,
410
]
],
[
[
1486,
25,
384
],
[
384,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nivolumab"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may ... | Methylprednisolone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Nivolumab
Methylprednisolone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when t... |
DB00427 | DB00794 | 1,233 | 759 | [
"DDInter1879",
"DDInter1521"
] | Triprolidine | Primidone | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
1233,
24,
759
]
],
[
[
1233,
24,
697
],
[
697,
40,
759
]
],
[
[
1233,
63,
362
],
[
362,
1,
759
]
],
[
[
1233,
24,
157
],
[
157,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (Comp... |
DB01253 | DB09074 | 628 | 1,362 | [
"DDInter664",
"DDInter1327"
] | Ergometrine | Olaparib | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
628,
24,
1362
]
],
[
[
628,
1,
588
],
[
588,
24,
1362
]
],
[
[
628,
24,
1478
],
[
1478,
24,
1362
]
],
[
[
628,
63,
353
],
[
353,
... | [
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Ergometrine",
"{u} (Compound) resembles {v} (Compound)",
"Methylergometrine"
],
[
"Methylergometrine",
"{u} may c... | Ergometrine (Compound) resembles Methylergometrine (Compound) and Methyl
Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Ergometrine may cause a moderate interacti... |
DB00307 | DB01126 | 1,101 | 1,260 | [
"DDInter202",
"DDInter611"
] | Bexarotene | Dutasteride | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestos... | Moderate | 1 | [
[
[
1101,
24,
1260
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
1260
]
],
[
[
1101,
21,
29308
],
[
29308,
60,
1260
]
],
[
[
1101,
24,
129
],
[
12... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dutasteride"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dutasteride (Compound)
Bexarotene (Compound) causes Breast pain (Side Effect) and Breast pain (Side Effect) is caused by Dutasteride (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide ... |
DB01254 | DB10276 | 1,213 | 1,624 | [
"DDInter484",
"DDInter1623"
] | Dasatinib | Rotavirus vaccine | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
1213,
25,
1624
]
],
[
[
1213,
63,
617
],
[
617,
24,
1624
]
],
[
[
1213,
63,
770
],
[
770,
25,
1624
]
],
[
[
1213,
25,
375
],
[
375,
... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budes... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and ... |
DB06589 | DB11793 | 1,250 | 738 | [
"DDInter1400",
"DDInter1297"
] | Pazopanib | Niraparib | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1250,
24,
738
]
],
[
[
1250,
24,
466
],
[
466,
63,
738
]
],
[
[
1250,
63,
1213
],
[
1213,
24,
738
]
],
[
[
1250,
24,
496
],
[
496,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasati... |
DB05015 | DB08870 | 1,077 | 850 | [
"DDInter174",
"DDInter228"
] | Belinostat | Brentuximab vedotin | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
1077,
24,
850
]
],
[
[
1077,
24,
496
],
[
496,
63,
850
]
],
[
[
1077,
63,
267
],
[
267,
24,
850
]
],
[
[
1077,
24,
259
],
[
259,
... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccin... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Belinostat may cause a moderate interaction that could exacerbate diseases when taken... |
DB00808 | DB01261 | 1,605 | 170 | [
"DDInter916",
"DDInter1679"
] | Indapamide | Sitagliptin | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
1605,
24,
170
]
],
[
[
1605,
6,
8374
],
[
8374,
45,
170
]
],
[
[
1605,
21,
28850
],
[
28850,
60,
170
]
],
[
[
1605,
24,
52
],
[
52,
... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Indapamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Indapamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)
Indapamide (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound)
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and D... |
DB00432 | DB00495 | 1,083 | 139 | [
"DDInter1868",
"DDInter1961"
] | Trifluridine | Zidovudine | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity... | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Moderate | 1 | [
[
[
1083,
24,
139
]
],
[
[
1083,
40,
11230
],
[
11230,
1,
139
]
],
[
[
1083,
1,
1477
],
[
1477,
40,
139
]
],
[
[
1083,
40,
231
],
[
231,
... | [
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Trifluridine",
"{u} (Compound) resembles {v} (Compound)",
"Idoxuridine"
],
[
"Idoxuridine",
"{u} (Compound) re... | Trifluridine (Compound) resembles Idoxuridine (Compound) and Idoxuridine (Compound) resembles Zidovudine (Compound)
Trifluridine (Compound) resembles Telbivudine (Compound) and Telbivudine (Compound) resembles Zidovudine (Compound)
Trifluridine (Compound) resembles Stavudine (Compound) and Stavudine (Compound) resemble... |
DB00005 | DB15233 | 1,057 | 1,650 | [
"DDInter687",
"DDInter142"
] | Etanercept | Avapritinib | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
1057,
25,
1650
]
],
[
[
1057,
25,
1101
],
[
1101,
24,
1650
]
],
[
[
1057,
24,
58
],
[
58,
24,
1650
]
],
[
[
1057,
25,
908
],
[
908,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} ... | Etanercept may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a... |
DB04865 | DB12498 | 4 | 76 | [
"DDInter1335",
"DDInter1238"
] | Omacetaxine mepesuccinate | Mogamulizumab | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become canc... | Moderate | 1 | [
[
[
4,
24,
76
]
],
[
[
4,
24,
1531
],
[
1531,
24,
76
]
],
[
[
4,
63,
58
],
[
58,
24,
76
]
],
[
[
4,
24,
987
],
[
987,
63,
76
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases wh... |
DB00717 | DB11979 | 1,197 | 1,320 | [
"DDInter1312",
"DDInter625"
] | Norethisterone | Elagolix | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1197,
24,
1320
]
],
[
[
1197,
24,
129
],
[
129,
24,
1320
]
],
[
[
1197,
24,
484
],
[
484,
63,
1320
]
],
[
[
1197,
63,
1051
],
[
1051,
... | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib... |
DB09039 | DB11732 | 1,670 | 1,097 | [
"DDInter629",
"DDInter1027"
] | Eliglustat | Lasmiditan | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
1670,
24,
1097
]
],
[
[
1670,
63,
1181
],
[
1181,
24,
1097
]
],
[
[
1670,
24,
971
],
[
971,
63,
1097
]
],
[
[
1670,
25,
384
],
[
384,
... | [
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
... | Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gi... |
DB00277 | DB00451 | 1,031 | 542 | [
"DDInter1791",
"DDInter1064"
] | Theophylline | Levothyroxine | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Moderate | 1 | [
[
[
1031,
24,
542
]
],
[
[
1031,
24,
624
],
[
624,
1,
542
]
],
[
[
1031,
6,
3486
],
[
3486,
45,
542
]
],
[
[
1031,
21,
29648
],
[
29648,
... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
],
... | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Liotrix and Liotrix (Compound) resembles Levothyroxine (Compound)
Theophylline (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Levothyroxine (Compound)
Theophylline (Compound) causes Disorientation (Side Effect) an... |
DB00285 | DB00668 | 1,100 | 874 | [
"DDInter1927",
"DDInter652"
] | Venlafaxine | Epinephrine | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Moderate | 1 | [
[
[
1100,
24,
874
]
],
[
[
1100,
24,
1636
],
[
1636,
1,
874
]
],
[
[
1100,
24,
688
],
[
688,
63,
874
]
],
[
[
1100,
6,
6017
],
[
6017,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine (Compound) resembles Epinephrine (Compound)
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction t... |
DB01218 | DB08912 | 1,493 | 1,040 | [
"DDInter852",
"DDInter462"
] | Halofantrine | Dabrafenib | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1493,
24,
1040
]
],
[
[
1493,
6,
3486
],
[
3486,
45,
1040
]
],
[
[
1493,
7,
5998
],
[
5998,
46,
1040
]
],
[
[
1493,
18,
2183
],
[
2183... | [
[
[
"Halofantrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Halofantrine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compoun... | Halofantrine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Dabrafenib (Compound)
Halofantrine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Dabrafenib (Compound)
Halofantrine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Dabrafenib (Compound)
Halofant... |
DB00035 | DB00214 | 1,314 | 1,028 | [
"DDInter507",
"DDInter1836"
] | Desmopressin | Torasemide | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Major | 2 | [
[
[
1314,
25,
1028
]
],
[
[
1314,
6,
10522
],
[
10522,
45,
1028
]
],
[
[
1314,
21,
29374
],
[
29374,
60,
1028
]
],
[
[
1314,
24,
1572
],
[
... | [
[
[
"Desmopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Torasemide"
]
],
[
[
"Desmopressin",
"{u} (Compound) binds {v} (Gene)",
"PTGS1"
],
[
"PTGS1",
"{u} (Gene) is bound by {v} (Compound)",
"Toras... | Desmopressin (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Torasemide (Compound)
Desmopressin (Compound) causes Oropharyngeal discomfort (Side Effect) and Oropharyngeal discomfort (Side Effect) is caused by Torasemide (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases w... |
DB00352 | DB00586 | 482 | 1,512 | [
"DDInter1814",
"DDInter537"
] | Tioguanine | Diclofenac | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
482,
24,
1512
]
],
[
[
482,
24,
1263
],
[
1263,
63,
1512
]
],
[
[
482,
6,
9320
],
[
9320,
45,
1512
]
],
[
[
482,
21,
28725
],
[
28725,... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac
Tioguanine (Compound) binds ABCC4 (Gene) and ABCC4 (Gene) is bound by Diclofenac (Compound)
Tioguanine (Compound) ... |
DB06772 | DB15091 | 310 | 676 | [
"DDInter259",
"DDInter1901"
] | Cabazitaxel | Upadacitinib | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
310,
25,
676
]
],
[
[
310,
63,
1461
],
[
1461,
23,
676
]
],
[
[
310,
63,
1430
],
[
1430,
24,
676
]
],
[
[
310,
24,
748
],
[
748,
... | [
[
[
"Cabazitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin... | Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipu... |
DB00019 | DB08889 | 1,257 | 350 | [
"DDInter1405",
"DDInter299"
] | Pegfilgrastim | Carfilzomib | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
1257,
24,
350
]
],
[
[
1257,
24,
1060
],
[
1060,
63,
350
]
],
[
[
1257,
24,
482
],
[
482,
24,
350
]
],
[
[
1257,
63,
1451
],
[
1451,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00222 | DB00722 | 245 | 743 | [
"DDInter825",
"DDInter1079"
] | Glimepiride | Lisinopril | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Moderate | 1 | [
[
[
245,
24,
743
]
],
[
[
245,
24,
610
],
[
610,
40,
743
]
],
[
[
245,
24,
1638
],
[
1638,
1,
743
]
],
[
[
245,
21,
29007
],
[
29007,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Lisinopril (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Lisinopril (Compou... |
DB00421 | DB01284 | 443 | 1,042 | [
"DDInter1707",
"DDInter1782"
] | Spironolactone | Tetracosactide | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
443,
24,
1042
]
],
[
[
443,
1,
1561
],
[
1561,
24,
1042
]
],
[
[
443,
23,
126
],
[
126,
24,
1042
]
],
[
[
443,
24,
123
],
[
123,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Spironolactone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
],
[
"Testosterone",
"{u} may... | Spironolactone (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Spironolactone may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction ... |
DB00342 | DB00816 | 1,181 | 1,674 | [
"DDInter1770",
"DDInter1346"
] | Terfenadine | Orciprenaline | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
1181,
24,
1674
]
],
[
[
1181,
24,
1164
],
[
1164,
24,
1674
]
],
[
[
1181,
63,
534
],
[
534,
24,
1674
]
],
[
[
1181,
25,
758
],
[
758,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Tramadol and... |
DB00377 | DB06603 | 1,494 | 39 | [
"DDInter1382",
"DDInter1387"
] | Palonosetron | Panobinostat | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1494,
25,
39
]
],
[
[
1494,
23,
1247
],
[
1247,
23,
39
]
],
[
[
1494,
24,
479
],
[
479,
23,
39
]
],
[
[
1494,
63,
867
],
[
867,
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Palonosetron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"... | Palonosetron may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Donepez... |
DB00035 | DB08918 | 1,314 | 41 | [
"DDInter507",
"DDInter1059"
] | Desmopressin | Levomilnacipran | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Moderate | 1 | [
[
[
1314,
24,
41
]
],
[
[
1314,
24,
901
],
[
901,
40,
41
]
],
[
[
1314,
21,
28643
],
[
28643,
60,
41
]
],
[
[
1314,
23,
1479
],
[
1479,
... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]... | Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Desmopressin (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Levomilnacipran (Compound)
Desmopressin may cause a min... |
DB00312 | DB00687 | 1,023 | 870 | [
"DDInter1423",
"DDInter747"
] | Pentobarbital | Fludrocortisone | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
1023,
24,
870
]
],
[
[
1023,
24,
1220
],
[
1220,
40,
870
]
],
[
[
1023,
21,
28762
],
[
28762,
60,
870
]
],
[
[
1023,
24,
392
],
[
392,... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Pentobarbital (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Fludrocortisone (Compound)
Pentobarbital may cause ... |
DB01073 | DB05773 | 1,488 | 1,047 | [
"DDInter745",
"DDInter1848"
] | Fludarabine | Trastuzumab emtansine | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
1488,
24,
1047
]
],
[
[
1488,
25,
375
],
[
375,
63,
1047
]
],
[
[
1488,
24,
381
],
[
381,
63,
1047
]
],
[
[
1488,
63,
1112
],
[
1112,
... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Fludarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
... | Fludarabine may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Sodium ... |
DB00222 | DB09104 | 245 | 286 | [
"DDInter825",
"DDInter1118"
] | Glimepiride | Magnesium hydroxide | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
245,
24,
286
]
],
[
[
245,
24,
820
],
[
820,
23,
286
]
],
[
[
245,
24,
1326
],
[
1326,
24,
286
]
],
[
[
245,
25,
839
],
[
839,
2... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Diclofenam... |
DB00078 | DB15091 | 1,172 | 676 | [
"DDInter898",
"DDInter1901"
] | Ibritumomab tiuxetan | Upadacitinib | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1172,
25,
676
]
],
[
[
1172,
24,
1430
],
[
1430,
24,
676
]
],
[
[
1172,
25,
283
],
[
283,
24,
676
]
],
[
[
1172,
63,
1184
],
[
1184,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],... | Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Fedratinib... |
DB00188 | DB00682 | 168 | 126 | [
"DDInter222",
"DDInter1951"
] | Bortezomib | Warfarin | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Minor | 0 | [
[
[
168,
23,
126
]
],
[
[
168,
23,
1335
],
[
1335,
40,
126
]
],
[
[
168,
25,
362
],
[
362,
24,
126
]
],
[
[
168,
6,
3486
],
[
3486,
... | [
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
]
],
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxcarbazepine"
],
[
... | Bortezomib may cause a minor interaction that can limit clinical effects when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Warfarin (Compound)
Bortezomib may lead to a major life threatening interaction when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate dis... |
DB00834 | DB01611 | 932 | 1,487 | [
"DDInter1215",
"DDInter893"
] | Mifepristone | Hydroxychloroquine | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
932,
25,
1487
]
],
[
[
932,
25,
1520
],
[
1520,
25,
1487
]
],
[
[
932,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
932,
21,
28658
],
[
2865... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Primaquine"
],
[
"Primaquine",
... | Mifepristone may lead to a major life threatening interaction when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Mifepristone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Mifepristone (Compound) caus... |
DB08873 | DB12010 | 74 | 214 | [
"DDInter221",
"DDInter785"
] | Boceprevir | Fostamatinib | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Major | 2 | [
[
[
74,
25,
214
]
],
[
[
74,
25,
976
],
[
976,
24,
214
]
],
[
[
74,
63,
723
],
[
723,
24,
214
]
],
[
[
74,
64,
866
],
[
866,
24,
... | [
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
]
],
[
[
"Boceprevir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{... | Boceprevir may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may ca... |
DB05015 | DB06674 | 1,077 | 908 | [
"DDInter174",
"DDInter837"
] | Belinostat | Golimumab | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
1077,
25,
908
]
],
[
[
1077,
24,
200
],
[
200,
63,
908
]
],
[
[
1077,
24,
1136
],
[
1136,
24,
908
]
],
[
[
1077,
63,
66
],
[
66,
... | [
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candi... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Denosumab ... |
DB00347 | DB00835 | 917 | 100 | [
"DDInter1871",
"DDInter245"
] | Trimethadione | Brompheniramine | An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378) | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
917,
24,
100
]
],
[
[
917,
24,
128
],
[
128,
24,
100
]
],
[
[
917,
6,
8374
],
[
8374,
45,
100
]
],
[
[
917,
63,
1242
],
[
1242,
... | [
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Trimethadione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbromphenirami... | Trimethadione may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Trimethadione (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bromphenirami... |
DB00468 | DB00637 | 1,424 | 1,557 | [
"DDInter1557",
"DDInter128"
] | Quinine | Astemizole | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Major | 2 | [
[
[
1424,
25,
1557
]
],
[
[
1424,
25,
1568
],
[
1568,
64,
1557
]
],
[
[
1424,
6,
21998
],
[
21998,
45,
1557
]
],
[
[
1424,
23,
307
],
[
30... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Astemizole"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimozide"
],
[
"Pimozide",
"{u} may lead to... | Quinine may lead to a major life threatening interaction when taken with Pimozide and Pimozide may lead to a major life threatening interaction when taken with Astemizole
Quinine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Astemizole (Compound)
Quinine may cause a minor interaction th... |
DB00214 | DB09043 | 1,028 | 135 | [
"DDInter1836",
"DDInter36"
] | Torasemide | Albiglutide | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
1028,
24,
135
]
],
[
[
1028,
24,
126
],
[
126,
23,
135
]
],
[
[
1028,
24,
870
],
[
870,
24,
135
]
],
[
[
1028,
63,
176
],
[
176,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludro... |
DB00964 | DB01501 | 1,617 | 1,118 | [
"DDInter110",
"DDInter549"
] | Apraclonidine | Difenoxin | Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist. | Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a ... | Moderate | 1 | [
[
[
1617,
24,
1118
]
],
[
[
1617,
24,
1688
],
[
1688,
40,
1118
]
],
[
[
1617,
63,
543
],
[
543,
1,
1118
]
],
[
[
1617,
63,
506
],
[
506,
... | [
[
[
"Apraclonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Apraclonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
],
... | Apraclonidine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate (Compound) resembles Difenoxin (Compound)
Apraclonidine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide (Compound) resembles Difenoxin (... |
DB00515 | DB08913 | 589 | 1,186 | [
"DDInter387",
"DDInter1561"
] | Cisplatin | Radium Ra 223 dichloride | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
589,
24,
1186
]
],
[
[
589,
21,
28872
],
[
28872,
60,
1186
]
],
[
[
589,
24,
37
],
[
37,
24,
1186
]
],
[
[
589,
63,
134
],
[
134,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Cisplatin",
"{u} (Compound) causes {v} (Side Effect)",
"Extravasation"
],
[
"Extravasation",
"{u} (... | Cisplatin (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when ... |
DB00275 | DB00860 | 217 | 891 | [
"DDInter1330",
"DDInter1513"
] | Olmesartan | Prednisolone | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, w... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
217,
24,
891
]
],
[
[
217,
24,
175
],
[
175,
40,
891
]
],
[
[
217,
24,
167
],
[
167,
1,
891
]
],
[
[
217,
21,
29232
],
[
29232,
... | [
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Predni... |
DB00572 | DB01324 | 85 | 178 | [
"DDInter136",
"DDInter1490"
] | Atropine | Polythiazide | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Minor | 0 | [
[
[
85,
23,
178
]
],
[
[
85,
23,
674
],
[
674,
40,
178
]
],
[
[
85,
62,
1014
],
[
1014,
40,
178
]
],
[
[
85,
21,
28835
],
[
28835,
6... | [
[
[
"Atropine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Polythiazide"
]
],
[
[
"Atropine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trichlormethiazide"
],
[
... | Atropine may cause a minor interaction that can limit clinical effects when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Atropine may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide (Compound) resembles Polythia... |
DB00041 | DB01206 | 1,648 | 37 | [
"DDInter38",
"DDInter1086"
] | Aldesleukin | Lomustine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
1648,
24,
37
]
],
[
[
1648,
23,
1176
],
[
1176,
23,
37
]
],
[
[
1648,
24,
697
],
[
697,
23,
37
]
],
[
[
1648,
23,
255
],
[
255,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moxifloxacin"
],
[
... | Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Lomustine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Ph... |
DB00361 | DB00564 | 134 | 1,236 | [
"DDInter1939",
"DDInter293"
] | Vinorelbine | Carbamazepine | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Moderate | 1 | [
[
[
134,
24,
1236
]
],
[
[
134,
23,
307
],
[
307,
1,
1236
]
],
[
[
134,
63,
362
],
[
362,
1,
1236
]
],
[
[
134,
24,
1335
],
[
1335,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Vinorelbine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Vinorelbine may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Carbamazepine (Compound)
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Carbamazepine (Compound... |
DB08880 | DB15699 | 1,510 | 652 | [
"DDInter1771",
"DDInter232"
] | Teriflunomide | Brexucabtagene autoleucel | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients rem... | Major | 2 | [
[
[
1510,
25,
652
]
],
[
[
1510,
64,
259
],
[
259,
24,
652
]
],
[
[
1510,
63,
1430
],
[
1430,
24,
652
]
],
[
[
1510,
25,
270
],
[
270,
... | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
],
[
"Rilo... | Teriflunomide may lead to a major life threatening interaction when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T an... |
DB00572 | DB01359 | 85 | 729 | [
"DDInter136",
"DDInter1417"
] | Atropine | Penbutolol | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
85,
24,
729
]
],
[
[
85,
63,
461
],
[
461,
1,
729
]
],
[
[
85,
24,
699
],
[
699,
40,
729
]
],
[
[
85,
21,
28698
],
[
28698,
60,
... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Ti... | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Atropine (Compou... |
DB00446 | DB04868 | 597 | 478 | [
"DDInter351",
"DDInter1293"
] | Chloramphenicol | Nilotinib | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
597,
24,
478
]
],
[
[
597,
24,
1468
],
[
1468,
63,
478
]
],
[
[
597,
6,
6017
],
[
6017,
45,
478
]
],
[
[
597,
7,
2692
],
[
2692,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Chloramphenicol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Chlorampheni... |
DB04855 | DB08871 | 540 | 36 | [
"DDInter602",
"DDInter666"
] | Dronedarone | Eribulin | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Major | 2 | [
[
[
540,
25,
36
]
],
[
[
540,
63,
973
],
[
973,
24,
36
]
],
[
[
540,
64,
1424
],
[
1424,
24,
36
]
],
[
[
540,
24,
28
],
[
28,
63,
... | [
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
]
],
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel... | Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Dronedarone may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a mode... |
DB01004 | DB01024 | 563 | 1,096 | [
"DDInter806",
"DDInter1252"
] | Ganciclovir | Mycophenolic acid | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Moderate | 1 | [
[
[
563,
24,
1096
]
],
[
[
563,
18,
1917
],
[
1917,
57,
1096
]
],
[
[
563,
21,
28759
],
[
28759,
60,
1096
]
],
[
[
563,
40,
387
],
[
387,
... | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Ganciclovir",
"{u} (Compound) downregulates {v} (Gene)",
"CDC25B"
],
[
"CDC25B",
"{u} (Gene) is downregu... | Ganciclovir (Compound) downregulates CDC25B (Gene) and CDC25B (Gene) is downregulated by Mycophenolic acid (Compound)
Ganciclovir (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Mycophenolic acid (Compound)
Ganciclovir (Compound) resembles Acyclovir (... |
DB01285 | DB06674 | 708 | 908 | [
"DDInter445",
"DDInter837"
] | Corticotropin | Golimumab | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
708,
25,
908
]
],
[
[
708,
63,
336
],
[
336,
24,
908
]
],
[
[
708,
24,
1586
],
[
1586,
63,
908
]
],
[
[
708,
24,
1136
],
[
1136,
... | [
[
[
"Corticotropin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifed... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine an... |
DB00081 | DB08908 | 273 | 713 | [
"DDInter1838",
"DDInter564"
] | Tositumomab | Dimethyl fumarate | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
273,
24,
713
]
],
[
[
273,
25,
4
],
[
4,
24,
713
]
],
[
[
273,
24,
270
],
[
270,
63,
713
]
],
[
[
273,
24,
1430
],
[
1430,
24,
... | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],... | Tositumomab may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00835 | DB01227 | 100 | 1,301 | [
"DDInter245",
"DDInter1043"
] | Brompheniramine | Levacetylmethadol | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Moderate | 1 | [
[
[
100,
24,
1301
]
],
[
[
100,
63,
494
],
[
494,
1,
1301
]
],
[
[
100,
24,
649
],
[
649,
1,
1301
]
],
[
[
100,
64,
675
],
[
675,
1,... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyrami... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Levacetylmethadol (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles L... |
DB00436 | DB09135 | 323 | 1,211 | [
"DDInter179",
"DDInter967"
] | Bendroflumethiazide | Ioxilan | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Moderate | 1 | [
[
[
323,
24,
1211
]
],
[
[
323,
40,
674
],
[
674,
24,
1211
]
],
[
[
323,
63,
1648
],
[
1648,
24,
1211
]
],
[
[
323,
24,
1287
],
[
1287,
... | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioxilan"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
],
[
"Trichlormethiazide",... | Bendroflumethiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Ioxilan
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause ... |
DB00501 | DB00969 | 752 | 2 | [
"DDInter380",
"DDInter52"
] | Cimetidine | Alosetron | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US marke... | Moderate | 1 | [
[
[
752,
24,
2
]
],
[
[
752,
6,
6017
],
[
6017,
45,
2
]
],
[
[
752,
21,
29058
],
[
29058,
60,
2
]
],
[
[
752,
24,
1401
],
[
1401,
62... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alosetron"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Cimetidine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Alosetron (Compound)
Cimetidine (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Alosetron (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Procainamide and Proc... |
DB00445 | DB14881 | 322 | 180 | [
"DDInter655",
"DDInter1329"
] | Epirubicin | Oliceridine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
322,
24,
180
]
],
[
[
322,
23,
112
],
[
112,
23,
180
]
],
[
[
322,
24,
401
],
[
401,
24,
180
]
],
[
[
322,
63,
1184
],
[
1184,
2... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Epirubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and P... |
DB00350 | DB01246 | 1,214 | 820 | [
"DDInter1226",
"DDInter45"
] | Minoxidil | Alimemazine | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1214,
24,
820
]
],
[
[
1214,
24,
358
],
[
358,
24,
820
]
],
[
[
1214,
24,
104
],
[
104,
40,
820
]
],
[
[
1214,
24,
675
],
[
675,
... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and M... |
DB00014 | DB01276 | 521 | 123 | [
"DDInter839",
"DDInter706"
] | Goserelin | Exenatide | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
521,
24,
123
]
],
[
[
521,
24,
867
],
[
867,
24,
123
]
],
[
[
521,
25,
839
],
[
839,
24,
123
]
],
[
[
521,
25,
1154
],
[
1154,
6... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olanzapine"
],
[
... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Goserelin may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cau... |
DB06772 | DB12267 | 310 | 1,476 | [
"DDInter259",
"DDInter233"
] | Cabazitaxel | Brigatinib | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
310,
24,
1476
]
],
[
[
310,
63,
168
],
[
168,
23,
1476
]
],
[
[
310,
63,
629
],
[
629,
24,
1476
]
],
[
[
310,
24,
800
],
[
800,
... | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolim... |
DB00726 | DB06176 | 1,164 | 1,342 | [
"DDInter1876",
"DDInter1616"
] | Trimipramine | Romidepsin | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
1164,
24,
1342
]
],
[
[
1164,
23,
112
],
[
112,
23,
1342
]
],
[
[
1164,
24,
485
],
[
485,
24,
1342
]
],
[
[
1164,
24,
1616
],
[
1616,
... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Trimipramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Trimipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and... |
DB00526 | DB01269 | 1,555 | 38 | [
"DDInter1355",
"DDInter1386"
] | Oxaliplatin | Panitumumab | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006. | Moderate | 1 | [
[
[
1555,
24,
38
]
],
[
[
1555,
24,
384
],
[
384,
63,
38
]
],
[
[
1555,
64,
494
],
[
494,
24,
38
]
],
[
[
1555,
64,
228
],
[
228,
25... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panitumumab"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Panitumumab
Oxaliplatin may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may... |
DB00358 | DB01142 | 1,010 | 1,264 | [
"DDInter1140",
"DDInter593"
] | Mefloquine | Doxepin | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1010,
24,
1264
]
],
[
[
1010,
24,
508
],
[
508,
24,
1264
]
],
[
[
1010,
6,
4973
],
[
4973,
45,
1264
]
],
[
[
1010,
21,
28954
],
[
2895... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Mefloquine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxepin (Compound)
Mefloquine (Compound) causes... |
DB01064 | DB09352 | 1,148 | 373 | [
"DDInter987",
"DDInter892"
] | Isoprenaline | Hydroxyamphetamine (ophthalmic) | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | 4-(2-aminopropyl)phenol is a member of amphetamines. | Moderate | 1 | [
[
[
1148,
24,
373
]
],
[
[
1148,
63,
480
],
[
480,
24,
373
]
],
[
[
1148,
24,
659
],
[
659,
24,
373
]
],
[
[
1148,
74,
1674
],
[
1674,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyamphetamine"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyamphetamine
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyam... |
DB00471 | DB05812 | 201 | 1,374 | [
"DDInter1242",
"DDInter8"
] | Montelukast | Abiraterone | Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montel... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
201,
24,
1374
]
],
[
[
201,
6,
8374
],
[
8374,
45,
1374
]
],
[
[
201,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
201,
24,
112
],
[
112,
... | [
[
[
"Montelukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Montelukast",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Montelukast (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Abiraterone (Compound)
Montelukast (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole ... |
DB05679 | DB08880 | 1,683 | 1,510 | [
"DDInter1907",
"DDInter1771"
] | Ustekinumab | Teriflunomide | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1683,
25,
1510
]
],
[
[
1683,
62,
1461
],
[
1461,
23,
1510
]
],
[
[
1683,
23,
1193
],
[
1193,
62,
1510
]
],
[
[
1683,
63,
608
],
[
608... | [
[
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Ustekinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin ... | Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc ... |
DB00624 | DB01097 | 1,561 | 1,377 | [
"DDInter1775",
"DDInter1033"
] | Testosterone | Leflunomide | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1561,
25,
1377
]
],
[
[
1561,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
1561,
21,
29231
],
[
29231,
60,
1377
]
],
[
[
1561,
25,
126
],
[
12... | [
[
[
"Testosterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Testosterone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Le... | Testosterone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Testosterone (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Leflunomide (Compound)
Testosterone may lead to a major life threatening interaction when taken with Warfarin and... |
DB06754 | DB12364 | 707 | 1,421 | [
"DDInter471",
"DDInter200"
] | Danaparoid | Betrixaban | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans. The active constituents are heparan, dermatan and, and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity tha... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
707,
25,
1421
]
],
[
[
707,
23,
297
],
[
297,
23,
1421
]
],
[
[
707,
23,
1631
],
[
1631,
62,
1421
]
],
[
[
707,
24,
992
],
[
992,
... | [
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Danaparoid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u... | Danaparoid may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Danaparoid may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a min... |
DB06674 | DB15091 | 908 | 676 | [
"DDInter837",
"DDInter1901"
] | Golimumab | Upadacitinib | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
908,
25,
676
]
],
[
[
908,
23,
1193
],
[
1193,
23,
676
]
],
[
[
908,
62,
1461
],
[
1461,
23,
676
]
],
[
[
908,
24,
1430
],
[
1430,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Golimumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc glu... | Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Golimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitam... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.